Resonance Health (ASX:RHT) — Material Events
ASX:RHT · 10 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Resonance Health Surges with Record Revenue and Breakthrough Tech TrialsMedium
Resonance Health reports record revenue, strong clinical trial progress, and new tech deployments
30 Jan 2026
·Quarterly Activities & Cashflow Report
·85
Resonance Health Advances Non-Invasive Liver Fibrosis MRI Device Amid FY26 GrowthMedium
Resonance Health advances MRI Liver Fibrosis Device with FY26 portfolio update and webinar
9 June 2026
·Investor Presentation
·85
Resonance Health Lifts FY26 EBITDA Forecast by 30 Percent on Margin GainsMedium
Resonance Health upgrades FY26 EBITDA guidance by 30% amid margin expansion and operational growth
5 May 2026
·Profit Guidance Upgrade
·85
Resonance Health Delivers $1.5M Profit on 42% Revenue Surge in FY26Medium
Resonance Health reports $1.5M profit and 42% revenue growth in FY26, driven by clinical trial and imaging software expansion
28 Aug 2026
·Annual Report
·85
Resonance Health Advances Clinical Trials and Secures Record SaMD ContractsMedium
Resonance Health reports positive cash flow, clinical trial progress, and record SaMD contracts
29 Oct 2025
·Quarterly Activities & Cashflow Report
·80
Resonance Health Nears $13.8M Trial Completion with Record $10M SaMD PipelineMedium
Resonance Health reports strong cash flow, near completion of $13.8M clinical trial, and record $10M+ SaMD order pipeline
29 Apr 2026
·Quarterly Activities & Cashflow Report
·80
Resonance Health Charts $17M Revenue Surge with AI-Driven Clinical ExpansionMedium
Resonance Health projects $17M revenue by FY26, driven by AI-enabled SaMD growth and global clinical trial expansion
13 Oct 2025
·Investor Presentation
·80
Resonance Health Posts Full-Year Positive Cash Flow and Clinical Trial MilestoneMedium
Resonance Health reports FY26 positive cash flow, clinical trial completion, and strong contract pipeline
24 July 2026
·Quarterly Activities and Cashflow Report
·80
Resonance Health Eyes $17M Revenue by FY26 with Strategic Market ExpansionMedium
Resonance Health projects strong revenue growth to $17M by FY26, maintains positive EBITDA guidance
13 Nov 2025
·Annual General Meeting Presentation
·80
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Resonance Health (ASX:RHT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Market Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026